￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

News

Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Effect data and adverse reactions of nivolumab in the treatment of advanced lung cancer

2025-10-19 11:44:20

Check Details
Dacomitinib can effectively prolong the survival of lung cancer patients

2025-10-19 11:44:20

Check Details
Second-generation ALK inhibitor: Alectinib, approved by FDA as first-line drug for ALK treatment

2025-10-19 11:44:20

Check Details
What is nivolumab? What conditions can be treated?

2025-10-19 11:44:20

Check Details
Alectinib for first-line treatment of ALK-positive advanced non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Has the innovative lung cancer drug dacomitinib been approved for marketing in China?

2025-10-19 11:44:20

Check Details
Xacori, the first drug approved for the treatment of ROS-1-positive non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Nivolumab has significant effect in treating non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Xalkori is used to treat ALK-positive locally advanced or metastatic non-small cell lung cancer

2025-10-19 11:44:20

Check Details
New drug for lung cancer; Dacomitinib can significantly improve progression-free survival of patients

2025-10-19 11:44:20

Check Details
ALK lung cancer drug Alectinib’s medical insurance reimbursement ratio in 2021

2025-10-19 11:44:20

Check Details
Contraindications and precautions for patients with lung cancer taking Xalkori

2025-10-19 11:44:20

Check Details
Category
相关知识